Luca Gianni

Fondazione Michelangelo — Italy

Medicine · Health Sciences

94h-index57.7kcitations595works15.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(202), Cancer Treatment and Pharmacology(192), Breast Cancer Treatment Studies(135), Advanced Breast Cancer Therapies(107), Monoclonal and Polyclonal Antibodies Research(70)

Publications590 total

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
npj Breast Cancer·2025Open Access
Abstract P4-05-29: ctDNA and serum thymidine kinase activity as tools to stratify ER+/HER2- metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibitors: preliminary results of the TIRESIAS trial
Clinical Cancer Research·2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study
ESMO Open·2025· 2 citedOpen Access
Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.
Journal of Clinical Oncology·2025
72P Predictive value of spatially-derived archetypes and tertiary lymphoid structure signature in the NeoTRIP trial
ESMO Open·2025Open Access
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Nature Communications·2025· 2 citedOpen Access
Data from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024· 1 citedOpen Access
Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Table S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Table S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Table S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure S7 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Table S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Data S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure S6 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Table S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
page 1 of 30Next →

Frequent Co-authors

Pinuccia Valagussa(10), Semiglazov Vf(10), José Baselga(8), David Cameron(8), José Baselga(8), Martine Piccart(7), Michael Untch(7), Giampaolo Bianchini(7), W. Eiermann(6), Aňa Lluch(6), Milvia Zambetti(6), Marion Procter(5), Aron Goldhirsch(5), Richard H. Bell(5), Christian Jackisch(5), Richard D. Gelber(5), Giulia Bianchi(5), Brian Leyland‐Jones(4), Ian Smith(4), Mitch Dowsett(4)